JMJunior De La Rosa Martinez

Junior De La Rosa Martinez

*This is an algorithmically generated author record based on publicly available information.

Junior De La Rosa Martinez has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Acetylation promotes thyroid hormone receptor ubiquitination and degradation by nuclear proteasomes

    by Sherena L. Christmas, Rebecca I. Strauss, Yigit K. Simsek, Matthew I. Rosenthal, Olivia A. White, Molly E. Shapira, Haytham Alsayed, Yu Yan, Junior De La Rosa Martinez, Vincent R. Roggero, et al.

  • Race Comparisons in Patients With Cardiac Sarcoidosis: Insights From the Cardiac Sarcoidosis Consortium

    by Angkawipa Trongtorsak, Junior De La Rosa Martinez, Thomas C. Crawford, Frank M. Bogun, Xiaokui Gu, Eric Puroll, Kenneth A. Ellenbogen, Alexandru B. Chicos, Henri Roukoz, Peter J. Zimetbaum, et al.

    BACKGROUND: Differences in cardiac sarcoidosis between racial groups remain understudied. Therefore, this study aims to explore race differences in patients with cardiac sarcoidosis. METHODS: We analyzed data from the Cardiac Sarcoidosis Consortium, an international registry including over 25 centers. The primary clinical outcome was a composite end point of all-cause mortality, left ventricular assist device implantation, heart transplantation, or implantable cardioverter defibrillator therapy. RESULTS: A total of 619 patients were included in the study (362 White, 193 Black, and 64 other races). Black patients were diagnosed with cardiac sarcoidosis at a younger age (50.5±11.8 versus 53.7±10.5 years old; P =0.010) compared with White patients. Left ventricular ejection fraction was significantly lower in Black patients (44.6±15.4 versus 48.3±14.0; P =0.008). In addition, extracardiac involvement in the lungs (80.3% versus 72.7%; P =0.046), skin (22.8% versus 12.4%; p =0.002), and eyes (13.5% versus 5.5%; P =0.001) was more prevalent in Black patients. Patients had significantly higher rates of hypertension (69.9% versus 50.6%; P P P P P 35% group (24.1% in Black versus 25.9% in White; P =0.72) and the left ventricular ejection fraction ≤35% group (51% versus 42.5%; P =0.35). CONCLUSIONS: Black patients with cardiac sarcoidosis exhibited significantly higher rates of lung, skin, and eye involvement and comorbidities, but had similar cardiac clinical outcomes and all-cause mortality compared with White patients. Nonetheless, ascertainment bias cannot be excluded.